Oxford University said trials of a coronavirus vaccine its developing with pharmaceutical company AstraZeneca will resume, days after pausing due to a reported side effect in a patient in Britain.
The university said in large trials “it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.”
It stated that globally some 18,000 individuals have received study vaccines as part of the trial.
It will not disclose the medical information about the illness for reasons of participant confidentiality but said it is “committed to the safety of our participants and the highest standards of conduct in our studies and will continue to monitor safety closely.”
Health experts explained pauses in drug trials are commonplace to ensure safety and effectiveness.
